By discovering the atomic structure of a key human enzyme, researchers at The University of Texas at Austin have pointed the way toward designing anti-HIV drugs with far less toxic side effects.
Their work was published this week in Cell.
“Many anti-HIV drugs are designed to stop the process of DNA replication,” says Dr. Whitney Yin, assistant professor of chemistry and biochemistry. “That turns out to be a great thing to do to help cure virus infections, because it stop the processes of viral replication.
“At the same time, however, when you target such a critical process in viruses, you may also target human enzymes that perform similar functions in normal cells, and this is what causes harmful drug side effects.”
Yin and her graduate student, Young-sam Lee, have solved the atomic structure of an enzyme, known as Pol γ (pol gamma), that is responsible for DNA replication in human mitochondria.
When mitochondria are working normally, they produce most of the energy that sustains human cells. When pol gamma comes into contact with certain anti-retroviral drugs, however, it can incorporate the drug into mitochondrial DNA, and thus interfere with the normal replication process. This interferes with the ability of mitochondria to function. The consequences can range from simple nausea to bone marrow depletion to organ failure.
“Patients who are taking this class of anti-HIV drugs have suffered these drug toxicities for a long time,” says Yin. “Dosages and combinations of drugs can be chosen so they don’t kill you, but they still can’t be used at their most effective concentrations against HIV. However, in large part because combination therapies have become more successful and patients are living longer, toxicity has become more of an issue than before.”
Although it’s been known for some time that pol gamma is responsible for mediating the toxicity of the drugs, Yin says, it has been difficult to design a drug that can distinguish between HIV and pol gamma without knowing the structure of pol gamma. With the structures of both pol gamma and HIV known, the differences between the two can be exploited in the design of new drugs that will be more selective (and thus less toxic) against HIV.
“This is a unique opportunity for drug design,” says Yin. “Now you have two pictures side by side. You have the viral target protein and the human protein. You know not to do anything in this region where the two proteins are similar, but rather focus in areas where they’re different.”
In addition to its relevance to anti-HIV drug design, Yin’s research is also helping to explain how mutations in pol gamma lead to various degenerative diseases, including epilepsy, encephalopathy and Alpers syndrome (a fatal childhood disease leading to brain and liver failure).
Yin’s research is funded by the National Institutes of Health (NIH) and the Welch Foundation.